Futuretech II Acquisition Corp. is advancing its proposed business combination with Longevity Biomedical, a move now being guided by a newly appointed exclusive financial advisor. This development marks a critical phase in the company’s de-SPAC process, even as it contends with significant internal obstacles, including an auditor resignation and concerns about its ability to continue operating.
Financial Advisor Appointment and Structural Adjustments
In a strategic step to solidify its merger plans, Futuretech II has engaged D. Boral Capital LLC as its exclusive financial advisor. Concurrent with this appointment, the company has issued a revised promissory note. The terms of this note explicitly tie the payment of deferred underwriting fees to the successful completion of the transaction with Longevity Biomedical. This structure directly aligns the SPAC’s financial obligations with the ultimate success of the merger.
These administrative actions unfold during a period of heightened scrutiny for the company. Documentation from early 2026 confirms the departure of its previous independent auditor and reveals existing warnings regarding its viability as a “going concern.” Futuretech II must also continue to meet all regulatory compliance standards set by exchange authorities to maintain its listing status.
Should investors sell immediately? Or is it worth buying Futuretech II AcquisitionUnit?
Regulatory Hurdles and Shareholder Approval Process
The immediate focus now shifts to the formal steps required to finalize the union. Market participants are awaiting the filing of definitive proxy materials, which will set the stage for a special shareholder meeting. At this meeting, investor approval for the deal with Longevity Biomedical will be sought.
The current market climate for Special Purpose Acquisition Companies (SPACs) targeting the biopharma and health technology sectors is highly selective. Analysts are paying close attention to how the company manages its liquidity constraints. The consolidation of its capital market relations under a single advisor could significantly shape the structure of any future equity or debt financing pursued after the merger concludes.
The transaction’s success hinges on Futuretech II’s ability to meet regulatory requirements in a timely manner and secure all necessary approvals. The coming weeks will test whether the new advisory framework is sufficient to bolster shareholder confidence ahead of the crucial vote.
Ad
Futuretech II AcquisitionUnit Stock: Buy or Sell?! New Futuretech II AcquisitionUnit Analysis from March 14 delivers the answer:
The latest Futuretech II AcquisitionUnit figures speak for themselves: Urgent action needed for Futuretech II AcquisitionUnit investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from March 14.
Futuretech II AcquisitionUnit: Buy or sell? Read more here...
